You are here: Industry Insights > xenleta

News List

XENLETA Demonstrates High Efficacy in Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
October 16, 2020
Nabriva Therapeutics announced in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 trials by age, XENLETA™ (lefamulin) demonstrated consistently high efficacy and similar safety and tolerability profiles across all ...
Nabriva Receives EC Approval for XENLETA for Community-Acquired Pneumonia americanpharmaceuticalreview
August 05, 2020
Nabriva Therapeutics announced the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults ...
Nabriva Receives Positive Opinion for XENLETA for Community-Acquired Pneumonia americanpharmaceuticalreview
June 09, 2020
Nabriva Therapeutics announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of XENLETA (lefamulin) for the treatment of community-acquired pneumonia..
New Antibiotic Xenleta Approved for Community-Acquired Bacterial Pneumonia drugs
August 20, 2019
Xenleta (lefamulin) has been approved to treat adults with community-acquired bacterial pneumonia, the U.S. Food and Drug Administration announced .